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Commercially available health technologies such as smartphones and smartwatches, activity trackers 62 
and eHealth applications, commonly referred to as wearables, are increasingly available and used both 63 
in the leisure and healthcare sector for pulse and fitness/ activity tracking. The aim of the Position Paper 64 
is to identify specific barriers and knowledge gaps for the use of wearables, in particular for heart rate 65 
and activity tracking, in clinical cardiovascular healthcare to support their implementation into clinical 66 
care. The widespread use of heart rate and fitness tracking technologies provides unparalleled 67 
opportunities for capturing physiological information from large populations in the community, which 68 
has previously only been available in patient populations in the setting of healthcare provision. The 69 
availability of low-cost and high-volume physiological data from the community also provides unique 70 
challenges. While the number of patients meeting healthcare providers with data from wearables is 71 
rapidly growing, there are at present no clinical guidelines on how and when to use data from wearables 72 
in primary and secondary prevention. Technical aspects of heart rate tracking especially during activity 73 
need to be further validated. How to analyze, translate, and interpret large datasets of information into 74 
clinically applicable recommendations needs further consideration. While the current users of wearable 75 
technologies tend to be young, healthy and in the higher sociodemographic strata, wearables could 76 
potentially have a greater utility in the elderly and higher risk population. Wearables may also provide 77 
a benefit through increased health awareness, democratization of health data and patient engagement. 78 
Use of continuous monitoring may provide opportunities for detection of risk factors and disease 79 
development earlier in the causal pathway, which may provide novel applications in both prevention 80 
and clinical research. However, wearables may also have potential adverse consequences due to 81 
unintended modification of behaviour, uncertain use and interpretation of large physiological data, a 82 
possible increase in social inequality due to differential access and technological literacy, challenges 83 
with regulatory bodies and privacy issues. In the present position paper, current applications as well as 84 
specific barriers and gaps in knowledge are identified and discussed in order to support the 85 
implementation of wearable technologies from gadget-ology into clinical cardiology. 86 




The last decade has seen a rapid increase in commercially available health technology such as 88 
smartphones and smartwatches, activity trackers and eHealth applications, commonly referred to as 89 
wearables. The worldwide wearable device sales is expected to reach 520 million units by 20251. 90 
Additionally, use of technologies capable of collecting physiological data may become even greater with 91 
widespread utilization of build-in smartphone sensors such as accelerometers, gyroscopes, video 92 
camera, microphones, skin conductance, as well as of other wearable technology2. These sensors have 93 
the capability of providing readily accessible physiological information at a population level, which was 94 
previously available only in patient populations in the setting of provision of healthcare. At present, 95 
heart rate monitoring and activity tracking are the two most prevalent physiological measurements 96 
generally available. Both heart rate and measures of physical fitness are known to be robustly related to 97 
cardiovascular disease and longevity3, 4. There is a long-standing tradition for remote monitoring in 98 
cardiology spanning from ambulatory heart rate monitoring to implantable devices such as pacemakers 99 
and implantable loop recorders5. Physicians are increasingly implementing wearables in their clinical 100 
practice6. However, how to use and understand the data collected from commercially available 101 
wearables for primary and secondary cardiovascular prevention is currently unclear, with no guidelines 102 
or recommendations in this area.  103 
The widespread availability of low-cost and high-volume physiological data from the community 104 
provides both unique opportunities and challenges. These issues need to be addressed in order to 105 
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AIMS & SCOPE 111 
Aim 112 
The aim of the present Position Paper is to identify specific barriers and knowledge gaps for the use of 113 
wearables, in particular for heart rate and activity tracking, in clinical cardiovascular healthcare to 114 
support their implementation into clinical care.  115 
Scope 116 
The scope of the present Position Paper, is focused on, but not limited to, use of wearables in primary 117 
and secondary prevention. In the current context, primary prevention is defined as prevention or delay 118 
of developing cardiovascular risk factors in healthy populations. Secondary prevention is defined as 119 
early cardiovascular disease detection and treatment in populations with known cardiovascular risk 120 
factors7.  121 
As the area of wearables is increasing exponentially in these years, the present Position Paper aims to 122 
provide a framework to constructively move the field forward from consumer products to clinical utility 123 
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SECTION 1: TECHNICAL ASPECTS  133 
Generally, current consumer devices provide heart rate (HR) estimates and heart rhythm information 134 
from one-lead electrocardiogram (ECG) or from the photoplethysmogram (PPG). An ECG can be 135 
obtained, for example, by chest straps wirelessly connected to a smartphone or smartwatch, or by a 136 
finger contact with a smartwatch crown. Using PPG, the sensor can be integrated into the smartphone, 137 
a wrist bracelet, an armband, or a smartwatch and the HR is estimated from the analysis of the pressure 138 
pulse detected by measuring changes in the LED light absorbed by the blood flowing into an artery8. 139 
Other methods are currently under development to estimate HR from precordial vibrations measured 140 
with miniaturized accelerometers9.  141 
In addition to single HR estimates, an increasing number of wearables enable continuous measurement 142 
of HR10 and thereby quantification of more advanced metrics such as HR variability (HRV) indices11.     143 
It is challenging to assess the accuracy of HR measurement by consumer devices as published studies 144 
present data of different subsets of devices tested through different protocols, applied in different 145 
populations, where the accuracy varies based on the subjects’ activity and the prevalence of arrythmias. 146 
Furthermore, the reported accuracy depends on which gold standard was used: for example, in some 147 
studies benchmarking was performed using consumer-grade ECG chest straps rather than clinical-grade 148 
ECG equipment, producing discordant results12, 13. There is a need for standardized protocols and 149 
measures for a robust appraisal of the accuracy of these consumer systems as well as for the definition 150 
of their operational limitations. 151 
The following general observations can be drawn:  152 
- accuracy differs among devices14, 15 153 
- accuracy decreases significantly with increasing activity level15, 16 154 
- during exercise, PPG from smartwatches tends to be more sensitive to motion artifacts than 155 
ECG from chest straps17. 156 
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Only few consumer-grade systems have received FDA clearance or CE mark as personal ECG monitors 157 
and irregular rhythm detectors (both from ECG or PPG), but with specific operational constraints and 158 
their ability to reliably identify atrial fibrillation is under evaluation18, 19.   159 
 160 
In addition, smartphone applications (apps) are also commonly used for HR/rhythm assessment. These 161 
apps can measure HR by turning the smartphone into a PPG detector20. Although some recent phones 162 
have a dedicated PPG sensor, in most cases the phone LED is exploited to illuminate the finger (to be 163 
positioned on the rear part of the phone), and the phone camera is used as PPG light-receptor21. The 164 
performance of HR measurement from a conventional ECG, a finger pulse oximeter and four PPG based 165 
smartphone applications have been compared22. It has been shown that HR estimates from ECG are well 166 
correlated with those from pulse oximetry, and from apps based on a PPG finger-contact measure.  An 167 
additional smartphone-based method relies on a non-contact PPG assessment (a video is made of the 168 
subject's face by the smartphone camera and PPG is derived from the changes of the red-color band of 169 
the image over time)23. Performances of this technique are found to be significantly lower than those 170 
obtained by the contact PPG21, 24, 25.   171 
Several consumer devices provide quantification of physical activity and posture obtained by the so-172 
called IMUs (Inertial Measurement Unit), i.e. electronic chips including a 3D accelerometer, a 3D 173 
gyroscope, and sometimes a magnetometer. While the hardware technology embedded in such devices 174 
is mature, the algorithms used to analyze the data are still in their infancy (i.e., distance measurements 175 
accuracy depending on speed). Hence, the raw data obtained by the sensors are reliable, but how this 176 
information is processed for quantification of a subject's activity and clinical utility needs more 177 
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GAPS IN KNOWLEDGE 183 
• Standardization of gold-standard to be used in validation protocols; for validation of HR-related 184 
measures, we recommend the use of clinical ECG equipment; for validation of activity 185 
measures, we recommend the use of video-camera recordings. 186 
• Exact definition of range of measures and conditions in which the accuracy has been tested 187 
should be defined (i.e., posture-dependent, range of HR, range of walking speed, subject 188 
population, and for PPG skin colour, external light conditions, contact pressure). 189 
• The variability (i.e. test-retest reliability), bias and limits of agreement of the measurements 190 
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SECTION 2: HEART RATE AND ACTIVITY TRACKING FOR PRIMARY AND 206 
SECONDARY PREVENTION 207 
Resting Heart Rate (RHR) 208 
In individuals from the background population without known cardiovascular disease, elevated resting 209 
heart rate (RHR) has been shown to be associated with higher blood pressure, higher body mass index, 210 
impaired pulmonary function, lower levels of physical activity and with increased subclinical chronic 211 
inflammation27-29. Although RHR is closely related to VO2max, its association with mortality is not 212 
explained by poor fitness alone30. There is consistent epidemiological evidence of a significant 213 
independent relationship between elevated RHR and increased risk of cardiovascular events and 214 
mortality in general populations29-34. While the majority of epidemiological research is based on single 215 
measurements of HR, few studies have investigated the association between temporal changes in HR 216 
and risk, which could be of greater relevance to wearable technologies34, 35. As a result, an increase in 217 
HR over time appears to be an indicator of deterioration of health36. Increased heart rate at rest has also 218 
been found to be associated with adverse events in patient populations such as heart failure37, chronic 219 
obstructive pulmonary disease38, diabetes39, and rheumatoid arthritis40. Despite the well-established 220 
association between elevated HR, cardiovascular risk factors, and risk of cardiovascular disease, there 221 
are currently no general recommendations to guide the general public or healthcare providers in this area 222 
but also no trials in the general population to show that interventions directed at elevated HR has an 223 
effect on clinical outcomes31.  224 
 225 
Heart Rate Variability (HRV) 226 
Beat-by-beat oscillations in RR interval (HRV) reflect the neural regulation on the cardiovascular 227 
system, providing a simple, non-invasive means to explore the complex and dynamic balance between 228 
sympathetic and parasympathetic cardiac neural influences in health and disease.11, 41 Low HRV is 229 
associated with a number of cardiovascular risk factors, such as diabetes and hypertension, and has been 230 
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shown to be associated with a 32-45% increase in the risk of development of a cardiovascular event in 231 
populations without known prevalent CVD42.  232 
The availability of wearable tools to measure HRV (and possibly also by coupling with blood pressure 233 
variability)41 opens new possibilities in risk prediction in secondary prevention. In particular, HRV and 234 
baroreflex sensitivity analysis may allow better characterization of cardiovascular neural modulation 235 
during sleep in normal and pathological conditions such as sleep apnea or serve as a prognostic tool in 236 
patients with established CV diseases. For example, low HRV has been shown to be independently 237 
predictive of increased mortality in post- myocardial infarction patients and heart failure patients43, 44. 238 
However, HRV analysis in clinical practice has never reached a wide utilization due to its limitations in 239 
acquisition protocols detecting specific diseases (i.e., a lower HRV could be associated to different 240 
causes, as well as unbalanced neural influences). 241 
 242 
Assessment of daily exercise behavior 243 
Improvement of physical activity behavior is an important treatment target in cardiovascular prevention. 244 
Numerous physical activity devices are currently commercially available, but their accuracy, however, 245 
is differing considerably during walking at normal speed. Moreover, accurate assessment of physical 246 
activity at lower speeds than usual walking was shown to be even more challenging.12 A recent 247 
systematic review of consumer-wearable activity trackers indicated a lower validity for assessment of 248 
energy expenditure as compared to step counts.45 Focusing on the cardiac patient population, recent 249 
findings also demonstrated a low accuracy and sensitivity for estimating changes in energy expenditure 250 
of modern activity trackers.46, 47 This illustrates the need for elaboration and definition of population-251 
specific exercise measurement algorithms. In this regard, it has been shown that the combination of heart 252 
rate and accelerometric data enhances device performance on energy expenditure estimation.48 253 
 254 
 255 
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GAPS IN KNOWLEDGE 256 
• Clinical utility of heart rate and fitness tracking for monitoring or as a target for intervention 257 
need to be determined.  258 
• Recommendations on healthy levels of heart rate at rest and during continuous activity are 259 
needed, as well as recommendations for when and how to intervene or refer to specialist care.  260 
• Methods or algorithms for translating data from continuous fitness or heart rate tracking into 261 
clinically meaningful information that can be used for primary and secondary prevention are 262 
needed. 263 
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SECTION 3: WHO WILL BENEFIT FROM WEARABLE TECHNOLOGY? 276 
Wearables, properly selected and adopted, might be useful for both high- and low-risk individuals in 277 
allowing the identification of subjects needing further investigation. 278 
The large and easy availability at population level make wearables the ideal technology for identification 279 
of early disease or monitoring of existing disease. For example, the use of wearables to objectively 280 
monitor physical activity can be of use in primary prevention, as it is well recognized that physical 281 
activity is inversely related to cardiovascular risk49. In addition, physical activity plays a dual role for 282 
patients who have experienced a cardiovascular event, both as part of cardiac rehabilitation, but also as 283 
a tool to monitor treatment effects. Physical activity is a dynamic parameter, and the use of wearables 284 
in heart failure populations have shown a correlation between decline in physical activity and cognitive 285 
decline50 showing the potential of wearable technologies to monitor disease states and indicate the need 286 
for intensified medical attention.  287 
The use of wearables as telemonitoring to reduce patient contacts may be beneficial for frail, immobile 288 
patients or in times of a pandemic5. Dedicated patient populations can use wearable devices for 289 
monitoring of disease-specific parameters, e.g. activity in heart failure patients43.  290 
Most currently available wearable tools are not ready to be considered medical devices, 46, 51 instead they 291 
offer a daily life approach to monitor well-being, such as physical activity in leisure-time or indicating 292 
the presence of irregular heartbeats. This can be done over relatively long time periods in a noninvasive 293 
manner, a possibility not easily allowed by conventional methods.  294 
 295 
Previously undetected arrhythmias  296 
Atrial Fibrillation 297 
In the large consumer-driven studies of wearables for detection of atrial fibrillation (AF), younger 298 
individuals dominate the study population, reflecting current ownership and adoption of wearable 299 
technology 19, 52. In contrast, AF prevalence and associated risks are mainly driven by increasing age 300 
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53. The performance of such wearable devices will depend on the prevalence of AF in the population 301 
that is studied. Younger participants (<40 years) also experience a larger number of false-positive 302 
alerts compared to the elderly 19, which may unnecessarily increase healthcare costs. In clinical studies 303 
focusing on high-risk individuals,  much more AF has been detected54, enabling stroke protective 304 
therapy and suggesting improved cost-effectiveness55. For wearables to have an impact on health in 305 
the population, the wearers of the devices need to be at risk of an adverse outcome and likely to 306 
benefit from preventative therapy.  The currently recruiting Heartline study (clinicaltrials.gov 307 
NCT04276441) aims to enrol 150.000 participants to evaluate if early AF diagnosis reduces the risk of 308 
thromboembolic events in a real-world setting. 309 
With regard to AF, risk factors for ischemic stroke, such as age or cardiovascular co-morbidities 310 
included in the CHA2DS2-VASc score, are generally those that are also associated with increased 311 
incidence of AF56. One would therefore expect that the use of wearables in the population, which is at 312 
an a priori greater risk for AF and its thromboembolic complications, would be associated with greater 313 
diagnostic yield and impact on risk management than indiscriminatory use of the technology in the 314 
population dominated by young and healthy (Figure 2).  315 
Management of known arrhythmias 316 
Wearable technologies have been proven useful, sometimes even beyond their indications for use as a 317 
medical device, for monitoring the effects of therapeutic interventions and documenting rhythm 318 
disorders underlying typical or atypical symptoms perceived to be caused by arrhythmias.57 A recent 319 
study showed that Apple Watch ECG tracings allowed adequate QT-interval measurements58 and 320 
thereby facilitated remote QT monitoring in quarantined outpatients receiving QT-prolonging 321 
treatments. However, it should be considered that in de novo classification request to FDA for the ECG 322 
app it is stated that “The clinical study did not quantitatively assess the quality of the ECG waveform 323 
produced by the ECG App. The ECG produced by the ECG App is not intended for clinical use or as 324 
the basis for diagnosis or treatment. The ECG waveform is only intended for informational use”. In the 325 
context of AF management, documentation of cardiac rhythm is pivotal for decision regarding the need 326 
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for re-ablation procedures or self-administration of rhythm-control drugs in situations when pill-in-the-327 
pocket strategy is employed. Nearly two thirds of patients with symptoms suggestive of AF do not have 328 
the arrhythmia, as shown in the studies using implantable loop recorders59. Wearables can provide a 329 
comprehensive AF management enhancing teleconsultation during and after a pandemic, like recently 330 
shown in the Telecheck-AF project60. 331 
 332 
GAPS IN KNOWLEDGE 333 
• Clinically relevant populations who would particularly benefit from use of wearables devices 334 
for heart rate and fitness monitoring should be defined. 335 
• Barriers, such as cost or technology literacy, should be identified and addressed in order to 336 
facilitate the use of wearables in at-risk populations. 337 
• While the wearable device ideally should be medically approved for clinical use, non-medically 338 
approved devices could contain clinically useful information. A therapeutic decision based on 339 
non-medical devices or off-label use of medical devices should therefore carefully weigh the 340 
source of data, validity of the information as well as clinical context before a clinical decision 341 
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SECTION 4: WEARABLES - A MEANS TO PATIENT EMPOWERMENT? 353 
 354 
Wearables are opening new avenues for patient engagement in self-management of cardiovascular 355 
health and in supporting shared decision making and goal setting. The European Society of Cardiology 356 
defines patient engagement as a set of behaviours by which patients take more responsibility for their 357 
own health care, and health care professionals take more account of patients’ health needs.61 Wearable 358 
technologies may facilitate this process by enabling patients to self-monitor a range of aspects of health, 359 
including activity, body weight, heart rate and rhythm, blood pressure, blood glucose, and fatigue.62 This 360 
may also promote dynamic exchange of data with health professionals through visualization. 361 
Visualization of health data has been mainly associated with electronic health records (EHR), gaining 362 
widespread adoption in the last two decades. A more recent approach aims to integrate data between 363 
EHR and medical devices, wearables and fitness tracking devices (a large number of existing wearables 364 
are EHR-compatible and this number is expected to increase exponentially). Mobile integration 365 
platforms, such as Google Fit and Apple HealthKit, pool data from multiple health apps and have the 366 
potential to integrate it with EHR, promoting visualization.63. However, there are concerns on data 367 
privacy and third-party utilization that would require further clarification. 368 
One of the most advanced applications of health visualization is building an avatar using health 369 
information from a wide range of sources, including wearables. This enables a level of personalization 370 
of health that is key in facilitation of behaviour change. Personalization or tailoring is defined as any of 371 
a number of methods for creating communications individualized for their receivers.64 Personalization 372 
techniques, such as gamification, rewarding, goal setting, feedback and inter-human interaction 373 
maximize the opportunity for personal engagement.65 Personally controlled data alters power dynamics 374 
in health care, improving democratization of health.  375 
 376 
 377 
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GAPS IN KNOWLEDGE 378 
- Value-based initiatives to increase patient activation and engagement using wearables are needed. 379 
- Studies exploring the ability of a technology to maintain engagement over time  (>3 or 6 months).   380 
- Tools and methods to characterize patient preference, increase personalization and improve 381 
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SECTION 5: WHAT ARE RELEVANT CLINICAL EVENTS OF INTEREST FOR 397 
PREVENTION USING WEARABLES? 398 
 399 
The use of continuous data using wearables is likely to challenge and expand our traditional way of 400 
thinking on clinical events of interest. Wearables have the potential to detect early markers of disease in 401 
“real-time” or with a close temporal relationship to physiological changes and are therefore particularly 402 
suited for prevention. The conventional endpoints used for preventive measures and clinical 403 
epidemiology typically include all-cause mortality, cause-specific mortality or single or aggregate 404 
comorbid endpoints based on administrative registers or other means of sampling information. Other 405 
cause-specific endpoints can be used, for instance incident atrial fibrillation or detection of other 406 
arrythmias. Ideally, a marker of risk should be detected before a traditional endpoint/ clinical event (e.g. 407 
manifest hypertension, atrial fibrillation, myocardial infarction, sudden death) occurs. More transient 408 
endpoints may be relevant– for instance, markers of physiological stress, and may potentially detect the 409 
very early markers of clinical events such as myocardial infarction or stroke. Heart rate monitors would 410 
be able to detect increase in heart rate at rest, increase in heart rate during night-time, or other 411 
physiological markers. With the introduction of other wearable sensors (e.g. blood glucose), the 412 
potential for early detection of disease and risk would increase. Increased resting heart rate has been 413 
shown to predict future hypertension66, which in turn is associated with increased risk of manifest 414 
cardiovascular disease. There is currently no recommendations, knowledge or consensus on how to 415 
advice individuals or the public in terms of very early markers of risk using wearable technology 416 
including heart rate or fitness trackers. 417 
Information from wearables may be particularly useful in nudging or educating patients or caregivers 418 
about the effects of patient activities, underlying medical conditions and treatments. Ideally, these 419 
devices also help to support diagnosis and to tailor treatment strategy. The potential value of this 420 
technology is that the feedback loop can be shortened by offering automated input for immediate 421 
modification of therapy and behaviour. In this context, the data generated should be diagnostically 422 
meaningful, informative regarding the treatment effect and of prognostic value. Wearables may 423 
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therefore allow a move towards “value-based pricing” (programs/drugs/interventions paid for if they 424 
lead to results) as well as allowing a more holistic assessment of the value of any intervention to that 425 
individual. 426 
GAPS IN KNOWLEDGE 427 
• Clinical endpoints and relevant events of interest need to be defined in the area of continuous 428 
monitoring in cardiovascular prevention.  429 
• Exploration of relevant immediate, intermediate or clinical endpoints are needed. 430 
• Research in the area of continuous heart rate and fitness tracking needs to be explored 431 
particularly for non-classical clinical endpoints such as quality of life and psychosocial factors.  432 
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SECTION 6: ARE THERE POTENTIAL ADVERSE CONSEQUENCES OF WEARABLES?  445 
 446 
There are several areas where wearable technology may have adverse consequences, including 447 
unintended modification of behavior, unintended creation of big datasets and its misuse, privacy and 448 
security issues, challenges facing regulatory bodies regarding safety and data interpretation, and lack of 449 
validation when used for health promotion.67  450 
Wearables provide feedback on physiological and exercise parameters, giving users an opportunity to 451 
modify health behaviours. In a minority of individuals, this may lead to increasing anxiety about health, 452 
to device addiction, or to self-diagnosis or even to self-medication or self-management of clinical 453 
conditions.68, 69 Patients could also suffer from negative consequences of excessive self-monitoring by 454 
finding it uncomfortable, intrusive, and unpleasant. Wearables may provide false assurances to the 455 
patient, with inaccuracy of activity trackers leading individuals to overestimate their level of physical 456 
activity, limiting the effectiveness for lifestyle interventions.70  457 
Users who buy wearable devices today do not necessarily “own” their data. Instead, the individual’s 458 
data is usually collected and stored on cloud severs by the manufacturer. This can create a paradox for 459 
the user in that they own the device, but not the captured data. The creation of such big datasets derived 460 
from an individual’s physiological data will have privacy and data storage / security implications, with 461 
the potential to expose patients to safety and cybersecurity risks, as has been the case in cardiac 462 
electronic implanted devices71, having their technology infected with malware and vulnerability to 463 
unauthorized access through hacking.  464 
Regulatory bodies do not regulate wearable sensors/ devices designed purely for lifestyle purposes, such 465 
as smartwatches that generally promote health and fitness.72 In contrast, apps with medical purposes 466 
(diagnosis, prevention, monitoring, treatment or alleviation of disease) are currently classified as 467 
“medical devices” by both the FDA73 and the European Union, where the new Medical Device 468 
Regulation (entering in force starting May 22 2021) will strengthen the rules for obtaining certification.  469 
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Also, wearable devices are marketed as a means to improve general health and fitness, but manufacturers 470 
are not required to provide data to support the accuracy and effectiveness of their products.  Furthermore, 471 
the use of wearables for cardiovascular health screening may medicalize healthy individuals, resulting 472 
in unnecessary medical investigations with possible patient harm and increased cost. False negatives 473 
can cause a potentially fatal condition to be missed while false positives can lead to overtreatment and/or 474 
anxiety.74  475 
Furthermore, wearables may contribute to increasing the health inequalities and inequities in society, 476 
where those without access to these technologies (because of economic considerations or digital literacy 477 
issues) may become more disadvantaged. However, with decrease in cost of wearables devices and 478 
higher penetration of digital literacy this challenge may be attenuated in the near future.  479 
Lastly, increased downstream testing and overtreatment with potential increase in cost and patient harm 480 
is a concern, especially when no clear definitions on indications for treatment or referral are established.  481 
 482 
GAPS IN KNOWLEDGE 483 
• Data to show efficacy of wearable devices in improvement of meaningful clinical outcomes 484 
in asymptomatic patients without clinically manifest cardiovascular diseases 485 
• The occurrence of unintended behavioural changes due to the use of devices and the 486 
resulting adverse clinical events in the population. 487 
• The health economic consequences of wearables should be determined, including benefits 488 




  07.01.2021 
22 
 
SECTION 7: DATA SECURITY AND PRIVACY OF HEART RATE AND ACTIVITY 493 
TRACKERS IN THE LIGHT OF NEW EUROPEAN LEGISLATION 494 
When dealing with wearable technology in the context of cardiovascular health promotion, knowledge 495 
of the current legislation at EU level is needed.  496 
The presence of a privacy policy is often lacking in most current commercially available heart rate and 497 
activity tracking technologies. In a review of the most downloaded health and fitness apps, the majority 498 
of apps did not have a privacy policy, while 74% of them gathered information classified as “sensitive”, 499 
sharing the collected data with a third party75.  500 
The EU General Data Protection Regulation (GDPR) 2016/679, effective since May 25 2018, has 501 
extended the concept of personal data to any information (a name, a photo, an email address, bank 502 
details, posts on social networking websites, medical information, or a computer IP, or also genetic, 503 
mental, cultural, economic and social data) related to a natural person or ‘Data Subject’ that can be used 504 
to directly or indirectly identify the person. Also, it has widened its jurisdiction, as it applies to all 505 
companies processing the personal data of data subjects residing in the EU, regardless of the company’s 506 
location. In addition, GDPR extends liability from Data controller to all parties that get in touch with 507 
the personal data, together with the principle to hold and process only the data absolutely necessary for 508 
the completion of its duties (data minimization principle), as well as not to change the use of the data 509 
from the purpose for which it was originally collected. These changes should be reflected in the consent 510 
form that is provided with any tracker or activity app that require the subject to be enrolled in order to 511 
access the service.  512 
The EU Medical Device Regulation (MDR) 2017/745, which will become effective starting May 26 513 
2021 extends the definition of medical device (any instrument intended by the manufacturer to be used 514 
for human beings for the purpose of diagnosis, prevention, monitoring, treatment or alleviation of 515 
disease) to prediction and prognosis, thus including all digital health apps that have an intrinsic tendency 516 
to collect and evaluate physiological data, including wellness technologies, as well as predictive models, 517 
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risk calculators, artificial intelligence. This could lead to the qualification as medical device for tools 518 
and software that are nowadays not under this category, as well as to the classification in higher classes 519 
of current class I medical devices, taking into account the intended purpose and the inherent risks76.  520 
In particular, software intended to monitor vital physiological parameters (heart rate, blood pressure, 521 
respiration) could be classified as Class IIb, if the nature of variations of those parameters could result 522 
in immediate danger to the patient (depending on patient disease and associated risk). 523 
 524 
GAPS IN KNOWLEDGE 525 
Current legislation is not specific for novel technologies, such as wearables, that need different criteria 526 
to be tested, verified, and updated. It is important that professional medical associations such as the ESC 527 
follow the process of creation of new legislation in this field and to inform lawmakers on specific needs 528 
and risks related to healthcare in general and wearable technology in particular. 529 
 530 
• It should be established to what extent healthcare professionals should be informed about data 531 
security and privacy of a device / health and fitness app. 532 
• It should be established in what way patients are informed about data storage and transfer to 533 
third parties when using a heart rate and activity tracker. 534 
• Data safety and integration with other health platforms should be addressed. 535 
• The ability of patients to opt out should be verified. 536 
• Standards for accreditation processes should be established to avoid relying on developer self-537 
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SECTION 8: Wearables and the COVID-19 Pandemic  543 
The pandemic of coronavirus disease (COVID-19), a disease caused by severe acute respiratory 544 
syndrome coronavirus 2 (SARS-CoV-2), has impacted clinical cardiology practice and the use of digital 545 
health. Patients with chronic cardiac diseases such as heart failure, arrhythmia, coronary artery disease, 546 
and congenital heart defects are traditionally followed including face-to-face contacts during outpatient 547 
visits77-79. Due to the COVID-19 pandemic, outpatient visits of chronic patients have been replaced by 548 
virtual visits to limit disease transmission80. Chronic cardiac patients need regular care and are at 549 
increased risk of infection with COVID-19 with worse outcome81. Wearables should be considered in 550 
these vulnerable patients to continue regular care82, to reduce risk of transmission, and to diagnose 551 
COVID-19 infection early83. Wearables can also supplement conventional diagnostic testing for public 552 
health surveillance to track (asymptomatic) persons who can transmit SARS-CoV-2 to others84. 553 
Wearables certified as medical devices have been shown able to track healthcare workers health status 554 
or to measure QT intervals85. Zhuo et al. demonstrated that medical and nursing staff with insomnia 555 
showed clear signs of comorbid sleep apnea attributable to stress86. Wearables can be used to perform 556 
monitoring of vital signs such as oxygen saturation, respiratory rate, blood pressure, body temperature, 557 
but also pulmonary auscultation, electrocardiograms, and cough monitoring87. SpO2 measurement is 558 
available as both stand-alone finger oximeters and as smart phone systems, although the accuracy of the 559 
latter has been questioned88. There are, however, also important challenges on wearables and COVID-560 
19. Whereas only a few COVID-19 wearables studies are expected to generate high-quality evidence, 561 
the majority of recently initiated studies are expected to have a concerning low level of evidence89. A 562 
joint decision with the patient (shared decision making) to switch to remote care with wearables is 563 
recommended. The many political, economic, and time-consuming barriers could be considered 564 
discouraging for a quick introduction of wearables to monitor cardiac diseases in the COVID-19 era. 565 
However, the COVID era without a doubt has been of enormous importance for the general adoption 566 
and clinical implementation of digital health and wearable devices. The rapid initiation could possibly 567 
lead to the much needed will and decisiveness to create sustainable tools, to arrange for financial 568 
compensation, and to perform high-quality clinical outcome studies. 569 
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GAPS IN KNOWLEDGE 570 
• Large-scale evidence of the efficacy of wearables to diagnose and manage COVID-19 in cardiac 571 
patients is lacking  572 
• The ideal physiological marker available for wearable technology to monitor, diagnose and 573 
manage COVID-19 with cardiac diseases need to be determined.  574 
• How to implement these findings from the individual user to a population level relevant for a 575 



















The introduction of wearables represents an unprecedented situation in primary and secondary 592 
prevention of cardiovascular disease in relation to availability of low-cost physiological data, 593 
“democratization” of health information, and possibility for early detection of disease or risk factors for 594 
disease. There are, however, significant issues and barriers that need to be addressed before wearables 595 
can be translated from nice-to-have consumer gadgets to clinical utility in the context of primary and 596 
secondary prevention. Health care providers are being presented with information from commercially 597 
available wearables with increasing frequency. However, there are presently no concrete guidelines for 598 
primary care physician or cardiologist on how to use, interpret or act on information from wearables. 599 
Even with the present absence of clinical evidence, the need for guidance is increasing to support the 600 
clinician faced with the daily challenges in the management of information from wearables. We 601 
encourage the professional associations of the European Society of Cardiology to develop clinical 602 
recommendations to guide the cardiologist in their respective fields.  The present Position Paper 603 
represents a constructive framework for directing future research and policy issues in relation to use of 604 
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Figure 1: Overview of Opportunities and Challenges in the use of Commercially Available Wearables 888 




















Figure 2: recommendations for screening of atrial fibrillation 906 
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